In this engaging discussion of these important therapies addressing critical unmet patient needs with curative intent, Dr. Cicchini touches on autologous cell therapy, where a patient’s own cells are used as the therapy; allogeneic cell therapy, using a donor’s cells; and gene therapy, where the DNA inside cells is changed to provide therapeutic benefit. With cell and gene therapy expanding in therapeutic areas like dermatology, immunology, ophthalmology, endocrinology, neurology, musculoskeletal, hematology and oncology, the FDA is predicting 10-20 new cell and gene therapy drug approvals annually by 2025. To support the complex and challenging patient journey, Dr. Cheng explains how his team focuses on enabling access to cell and gene therapies, collaborating with developers to enhance distribution, streamline logistics, and provide comprehensive patient support. He shares an example of a patient suffering from ALD making his way through the process, then discusses the significantly higher production costs of cell and gene therapies and how that compares to their value. 

Join Beth Mitchell, VP, US Public Policy and Advocacy for a state of the union on Public Policy and Advocacy. Beth will cover key updates that took place in 2023, along with what has occurred so far in 2024. She will also touch on how Cencora is partnering to make change in this space. Please join us for an insightful discussion during this webinar!